\-\ Texto\\:\\ \ \(0\)\
\-\ general\\:\\ \\ well\\-nourished\\,\\ well\\-appearing\\,\\ no\\ acute\\ distress\\.\\ \ \(0\)\
\-\ musculoskeletal\\:\\ \\ point\\ tenderness\\ over\\ lateral\\ aspect\\ of\\ knee\\,\\ slightly\\ below\\ the\\ joint\\ line\\.\\ \\ approximately\\ a\\ 2\\ cm\\ hard\\ nodule\\ felt\\ on\\ palpation\\.\\ \\ nodule\\ is\\ non\\-mobile\\.\\ \\ no\\ erythema\\,\\ swelling\\,\\ tenderness\\.\ \(0\)\
\-\ laboratory\\:\\ \\ unremarkable\ \(0\)\
\-\ patient\\ was\\ referred\\ to\\ outpatient\\ management\\ for\\ further\\ workup\\ of\\ the\\ lytic\\ lesion\\ and\\ excisional\\ removal\\ with\\ wide\\ margins\\.\ \(0\)\
\-\ anteroposterior\\,\\ lateral\\ and\\ tunnel\\ radiographs\\ of\\ the\\ right\\ knee\\ show\\ an\\ expansile\\ lytic\\ lesion\\ of\\ the\\ proximal\\ fibula\\ with\\ fairly\\ narrow\\ zone\\ of\\ transition\\.\\ \\ lesion\\ measures\\ approximately\\ 4\\.0\\ x\\ 3\\.9\\ cm\\ ap\\ x\\ lr\\ and\\ extends\\ approximately\\ 7\\.0\\ cm\\ si\\.\\ \\ \ \(0\)\
\-\ on\\ bone\\ scans\\,\\ mass\\ demonstrates\\ \\ that\\ increased\\ radiotracer\\ accumulation\\,\\ with\\ suggestion\\ of\\ a\\ mild\\ photopenic\\ area\\ centrally\\.\\ \\ tibia\\ and\\ femur\\ are\\ otherwise\\ normal\\ in\\ appearance\\.\\ no\\ additional\\ abnormal\\ radiotracer\\ uptake\\ throughout\\ the\\ remainder\\ of\\ the\\ regions\\ of\\ the\\ left\\ and\\ right\\ knees\\.\\ no\\ associated\\ periosteal\\ reaction\\ or\\ soft\\ tissue\\ mass\\.\\ \\ \\ normal\\ soft\\ tissue\\ radiolabel\\ uptake\\.\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumor\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumor\ \(0\)\
\-\ aneurysmal\\ bone\\ cyst\ \(11\)\
\-\ brown\\ tumors\\ of\\ hyperparathyroidism\ \(0\)\
\-\ malignant\\ fibrous\\ histiocytomas\ \(2\)\
\-\ chondroblastomas\ \(2\)\
\-\ lytic\\ metastasis\ \(2\)\
\-\ telangiectatic\\ osteosarcoma\ \(2\)\
\-\ 21\\ year\\ old\\ woman\\,\\ complaining\\ about\\ pain\\ in\\ her\\ right\\ knee\\ for\\ the\\ past\\ 4\\ months\\.\\ \\ pain\\ has\\ gradually\\ increased\\ in\\ intensity\\,\\ interfering\\ with\\ her\\ fitness\\ routine\\.\\ \\ \\ pain\\ is\\ not\\ worse\\ during\\ the\\ mornings\\ or\\ at\\ night\\.\\ \\ no\\ fevers\\,\\ chills\\ nor\\ night\\ sweats\\.\ \(0\)\
\-\ giant\\ cell\\ bone\\ tumors\\ are\\ destructive\\ lesions\\ of\\ bone\\ that\\ may\\ be\\ well\\-defined\\ althoughs\\ sometimes\\ aggressive\\.\\ \\ \\ giant\\ cells\\ are\\ large\\ cells\\ which\\ consist\\ of\\ fused\\ stromal\\ cells\\.\\ \\ these\\ tumors\\ are\\ very\\ rare\\,\\ affecting\\ approximately\\ one\\ a\\ million\\,\\ usually\\ between\\ the\\ ages\\ of\\ 25\\ and\\ 40\\,\\ with\\ most\\ tumors\\ occurring\\ in\\ the\\ 30\\â\\€\\™s\\.\\ \\ women\\ are\\ affected\\ slightly\\ more\\ than\\ men\\ \\(50\\-57\\%\\)\\.\\ \\ \\ this\\ syndrome\\ does\\ not\\ have\\ a\\ genetic\\ link\\,\\ nor\\ a\\ known\\ cause\\.\ \(0\)\
\-\ reference\\:\ \(0\)\
\-\ resnick\\ d\\.\\ tumors\\ and\\ tumor\\-like\\ lesion\\ of\\ bone\\:\\ imaging\\ and\\ pathology\\ of\\ specific\\ lesions\\.\\ in\\ resnick\\ d\\,\\ ed\\.\\ we\\.\\ saunders\\ co\\.\\ vol\\ 6\\ 1995\\;\\ pp3787\\-3806\ \(0\)\
\-\ giant\\ cell\\ tumors\\ are\\ seen\\ on\\ radiographs\\ as\\ expansive\\ osteolytic\\ lesions\\ surrounded\\ by\\ a\\ thin\\ rim\\ of\\ white\\ bone\\.\\ \\ they\\ are\\ usually\\ near\\ a\\ joint\\,\\ with\\ 60\\%\\ occurring\\ at\\ the\\ epimetaphyseal\\ region\\ of\\ long\\ bones\\.\\ \\ fifty\\ percent\\ occur\\ around\\ the\\ knee\\ joint\\.\\ \\ they\\ are\\ almost\\ exclusively\\ seen\\ when\\ the\\ epiphysis\\ of\\ the\\ bone\\ is\\ closed\\.\\ \\ in\\ 5\\-10\\%\\,\\ these\\ tumors\\ may\\ metastasize\\ to\\ the\\ lungs\\.\ \(0\)\
\-\ giant\\ cell\\ tumors\\ present\\ with\\ progressive\\ pain\\ as\\ the\\ bone\\ tumor\\ irritates\\ the\\ periosteum\\ and\\ sometimes\\ leads\\ to\\ a\\ pathologic\\ fracture\\.\\ \ \(0\)\
\-\ treatment\\ is\\ surgical\\ \\â\\€\\“\\ intralesional\\ excision\\ with\\ extensive\\ curettage\\ or\\ may\\ be\\ resection\\ depending\\ upon\\ the\\ extension\\ outside\\ the\\ bone\\ and\\ into\\ the\\ joint\\.\\ \\ various\\ methods\\ are\\ available\\ to\\ ensure\\ tumor\\ cell\\ destruction\\.\\ \\ the\\ lytic\\ lesion\\ is\\ stabilized\\ with\\ cement\\ or\\ bone\\ graft\\.\\ \\ non\\-weight\\ bearing\\ bones\\ may\\ be\\ simply\\ removed\\ with\\ wide\\ excision\\.\\ \\ patients\\ with\\ lung\\ metastases\\ should\\ be\\ further\\ evaluated\\ for\\ resection\\ of\\ metastases\\(which\\,\\ surprisingly\\,\\ may\\ not\\ be\\ necessary\\)\\.\ \(0\)\
\-\ prognosis\\ is\\ good\\,\\ even\\ with\\ metastatic\\ disease\\.\\ \\ local\\ recurrence\\ rates\\ are\\ high\\,\\ with\\ a\\ 10\\%\\ to\\ 50\\%\\ recurrence\\ rate\\.\\ \\ patients\\ should\\ be\\ periodically\\ followed\\ for\\ 2\\ years\\ after\\ excision\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tumors\\:\\ 0\\.0443484125412159\ \(0\)\
\-\ bone\\:\\ 0\\.04400900894217347\ \(0\)\
\-\ giant\\:\\ 0\\.042642881431855774\ \(0\)\
\-\ lytic\\:\\ 0\\.026425463469345503\ \(0\)\
\-\ cell\\:\\ 0\\.02391959286612939\ \(0\)\
\-\ knee\\:\\ 0\\.02140580810058913\ \(0\)\
\-\ resnick\\:\\ 0\\.020664266251848987\ \(0\)\
\-\ are\\:\\ 0\\.02011871973280832\ \(0\)\
\-\ joint\\:\\ 0\\.0190910483940731\ \(0\)\
\-\ approximately\\:\\ 0\\.018264717281903854\ \(0\)\
\-\ excision\\:\\ 0\\.018172283557333125\ \(0\)\
\-\ cells\\:\\ 0\\.017753609814248693\ \(0\)\
\-\ \\%\\:\\ 0\\.017213480426131328\ \(0\)\
\-\ occurring\\:\\ 0\\.016485206066086177\ \(0\)\
\-\ may\\:\\ 0\\.016185909921400034\ \(0\)\
\-\ wide\\:\\ 0\\.015825257061724485\ \(0\)\
\-\ nor\\:\\ 0\\.015775555032528976\ \(0\)\
\-\ althoughs\\:\\ 0\\.015225420421358373\ \(0\)\
\-\ 50\\-57\\:\\ 0\\.015225420421358373\ \(0\)\
\-\ tumor\\-like\\:\\ 0\\.015225420421358373\ \(0\)\
\-\ pp3787\\-3806\\:\\ 0\\.015225420421358373\ \(0\)\
\-\ lesion\\:\\ 0\\.015030701433509971\ \(0\)\
\-\ sometimes\\:\\ 0\\.01502456064011024\ \(0\)\
\-\ night\\:\\ 0\\.01434224293559389\ \(0\)\
\-\ radiolabel\\:\\ 0\\.014028275031790246\ \(0\)\
\-\ mornings\\:\\ 0\\.014028275031790246\ \(0\)\
\-\ epimetaphyseal\\:\\ 0\\.014028275031790246\ \(0\)\
\-\ irritates\\:\\ 0\\.014028275031790246\ \(0\)\
\-\ radiotracer\\:\\ 0\\.01377272776049809\ \(0\)\
\-\ tumor\\:\\ 0\\.01376326287814032\ \(0\)\
\-\ be\\:\\ 0\\.013655510086465587\ \(0\)\
\-\ histiocytomas\\:\\ 0\\.013327989870981672\ \(0\)\
\-\ chondroblastomas\\:\\ 0\\.013327989870981672\ \(0\)\
\-\ interfering\\:\\ 0\\.013327989870981672\ \(0\)\
\-\ expansive\\:\\ 0\\.013327989870981672\ \(0\)\
\-\ recurrence\\:\\ 0\\.012877105660566887\ \(0\)\
\-\ surprisingly\\:\\ 0\\.01283112964222212\ \(0\)\
\-\ metastases\\:\\ 0\\.012610474784259012\ \(0\)\
\-\ bones\\:\\ 0\\.012456070021157435\ \(0\)\
\-\ lr\\:\\ 0\\.012445734907655263\ \(0\)\
\-\ fitness\\:\\ 0\\.012445734907655263\ \(0\)\
\-\ million\\:\\ 0\\.012445734907655263\ \(0\)\
\-\ nodule\\:\\ 0\\.0121665409300242\ \(0\)\
\-\ slightly\\:\\ 0\\.01193169691971355\ \(0\)\
\-\ cm\\:\\ 0\\.011875420299569875\ \(0\)\
\-\ well\\-appearing\\:\\ 0\\.011864608419535724\ \(0\)\
\-\ telangiectatic\\:\\ 0\\.011864608419535724\ \(0\)\
\-\ fifty\\:\\ 0\\.011864608419535724\ \(0\)\
\-\ lesions\\:\\ 0\\.011852645110590403\ \(0\)\
\-\ uptake\\:\\ 0\\.01172705846181075\ \(0\)\
\-\ 7\\.0\\:\\ 0\\.011633984252653993\ \(0\)\
\-\ cement\\:\\ 0\\.011633984252653993\ \(0\)\
\-\ periodically\\:\\ 0\\.011633984252653993\ \(0\)\
\-\ co\\:\\ 0\\.011430559320604971\ \(0\)\
\-\ 4\\.0\\:\\ 0\\.010933699091845418\ \(0\)\
\-\ intralesional\\:\\ 0\\.010933699091845418\ \(0\)\
\-\ well\\-nourished\\:\\ 0\\.010795456073410986\ \(0\)\
\-\ non\\-mobile\\:\\ 0\\.010795456073410986\ \(0\)\
\-\ non\\-weight\\:\\ 0\\.010667463029967598\ \(0\)\
\-\ they\\:\\ 0\\.01063539249218413\ \(0\)\
\-\ 3\\.9\\:\\ 0\\.010548304357278562\ \(0\)\
\-\ photopenic\\:\\ 0\\.010436838863085865\ \(0\)\
\-\ metastasize\\:\\ 0\\.010436838863085865\ \(0\)\
\-\ simply\\:\\ 0\\.010436838863085865\ \(0\)\
\-\ stabilized\\:\\ 0\\.010332133125924493\ \(0\)\
\-\ \\,\\:\\ 0\\.010286047394439245\ \(0\)\
\-\ tunnel\\:\\ 0\\.01014003358341979\ \(0\)\
\-\ 5\\-10\\:\\ 0\\.01014003358341979\ \(0\)\
\-\ methods\\:\\ 0\\.01014003358341979\ \(0\)\
\-\ excisional\\:\\ 0\\.01005144412851901\ \(0\)\
\-\ si\\:\\ 0\\.01005144412851901\ \(0\)\
\-\ exclusively\\:\\ 0\\.01005144412851901\ \(0\)\
\-\ osteolytic\\:\\ 0\\.009967177869159023\ \(0\)\
\-\ periosteum\\:\\ 0\\.009967177869159023\ \(0\)\
\-\ vol\\:\\ 0\\.009886832419012405\ \(0\)\
\-\ anteroposterior\\:\\ 0\\.009810059081238944\ \(0\)\
\-\ \\:\\:\\ 0\\.00976057699473804\ \(0\)\
\-\ x\\:\\ 0\\.009737707548695948\ \(0\)\
\-\ brown\\:\\ 0\\.009736553702277292\ \(0\)\
\-\ link\\:\\ 0\\.00959831068384286\ \(0\)\
\-\ consist\\:\\ 0\\.009533128770228272\ \(0\)\
\-\ should\\:\\ 0\\.009410046776817962\ \(0\)\
\-\ further\\:\\ 0\\.009386680973403309\ \(0\)\
\-\ radiographs\\:\\ 0\\.009348085807261253\ \(0\)\
\-\ saunders\\:\\ 0\\.009239693473517739\ \(0\)\
\-\ resection\\:\\ 0\\.009205235424940306\ \(0\)\
\-\ stromal\\:\\ 0\\.00918654725820383\ \(0\)\
\-\ curettage\\:\\ 0\\.00918654725820383\ \(0\)\
\-\ 1995\\:\\ 0\\.009134987736356367\ \(0\)\
\-\ tenderness\\:\\ 0\\.00897724463862395\ \(0\)\
\-\ usually\\:\\ 0\\.008963482742199512\ \(0\)\
\-\ suggestion\\:\\ 0\\.008942888193851662\ \(0\)\
\-\ her\\:\\ 0\\.008875342516355562\ \(0\)\
\-\ destructive\\:\\ 0\\.008854298738950883\ \(0\)\
\-\ fused\\:\\ 0\\.008854298738950883\ \(0\)\
\-\ d\\.\\:\\ 0\\.008770032479590897\ \(0\)\
\-\ graft\\:\\ 0\\.008729392587690734\ \(0\)\
\-\ fairly\\:\\ 0\\.008650873806901863\ \(0\)\
\-\ transition\\:\\ 0\\.008612913691670818\ \(0\)\
\-\ fibula\\:\\ 0\\.008575769986625976\ \(0\)\
\-\ knees\\:\\ 0\\.008575769986625976\ \(0\)\
\-\ gradually\\:\\ 0\\.008575769986625976\ \(0\)\
\-\ ensure\\:\\ 0\\.008575769986625976\ \(0\)\
\-\ rates\\:\\ 0\\.008575769986625976\ \(0\)\
\-\ bearing\\:\\ 0\\.008539408312709166\ \(0\)\
\-\ surrounded\\:\\ 0\\.008434702575547792\ \(0\)\
\-\ outpatient\\:\\ 0\\.008401165294274732\ \(0\)\
\-\ sweats\\:\\ 0\\.008401165294274732\ \(0\)\
\-\ ages\\:\\ 0\\.008368266857365072\ \(0\)\
\-\ men\\:\\ 0\\.008335983380660144\ \(0\)\
\-\ leads\\:\\ 0\\.008242603033043088\ \(0\)\
\-\ affecting\\:\\ 0\\.008212565480863694\ \(0\)\
\-\ various\\:\\ 0\\.00815401357814231\ \(0\)\
\-\ hard\\:\\ 0\\.008125465560955418\ \(0\)\
\-\ epiphysis\\:\\ 0\\.008097381759795175\ \(0\)\
\-\ genetic\\:\\ 0\\.008069747318782324\ \(0\)\
\-\ centrally\\:\\ 0\\.008042548083949613\ \(0\)\
\-\ percent\\:\\ 0\\.008042548083949613\ \(0\)\
\-\ aneurysmal\\:\\ 0\\.008015770559707876\ \(0\)\
\-\ closed\\:\\ 0\\.007989401868635703\ \(0\)\
\-\ narrow\\:\\ 0\\.007963429714292801\ \(0\)\
\-\ reference\\:\\ 0\\.007937842346788241\ \(0\)\
\-\ accumulation\\:\\ 0\\.007863279010233476\ \(0\)\
\-\ zone\\:\\ 0\\.007839123151900593\ \(0\)\
\-\ we\\:\\ 0\\.007768618843575454\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.0077457428042835355\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.0077231658067578824\ \(0\)\
\-\ these\\:\\ 0\\.007681674238196338\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.007678878361829839\ \(0\)\
\-\ depending\\:\\ 0\\.007678878361829839\ \(0\)\
\-\ patients\\:\\ 0\\.007639290498673664\ \(0\)\
\-\ workup\\:\\ 0\\.00759357135780639\ \(0\)\
\-\ well\\-defined\\:\\ 0\\.00759357135780639\ \(0\)\
\-\ no\\:\\ 0\\.007430433080343713\ \(0\)\
\-\ chills\\:\\ 0\\.007378624597057849\ \(0\)\
\-\ d\\:\\ 0\\.0073603480697166795\ \(0\)\
\-\ destruction\\:\\ 0\\.00728911670782713\ \(0\)\
\-\ erythema\\:\\ 0\\.0072545732420125015\ \(0\)\
\-\ expansile\\:\\ 0\\.007237557185979666\ \(0\)\
\-\ increased\\:\\ 0\\.007221018244558396\ \(0\)\
\-\ aggressive\\:\\ 0\\.007220707142896135\ \(0\)\
\-\ pain\\:\\ 0\\.0072097282730966125\ \(0\)\
\-\ complaining\\:\\ 0\\.007204019904706607\ \(0\)\
\-\ soft\\:\\ 0\\.007188002639010535\ \(0\)\
\-\ women\\:\\ 0\\.007171121467796945\ \(0\)\
\-\ almost\\:\\ 0\\.007138837991092018\ \(0\)\
\-\ fevers\\:\\ 0\\.007015420091295568\ \(0\)\
\-\ periosteal\\:\\ 0\\.007000594972657585\ \(0\)\
\-\ prognosis\\:\\ 0\\.007000594972657585\ \(0\)\
\-\ tissue\\:\\ 0\\.00699627353524212\ \(0\)\
\-\ remainder\\:\\ 0\\.006956868188574184\ \(0\)\
\-\ felt\\:\\ 0\\.006942535195802689\ \(0\)\
\-\ or\\:\\ 0\\.006918982721683644\ \(0\)\
\-\ scans\\:\\ 0\\.006872601929214197\ \(0\)\
\-\ tibia\\:\\ 0\\.0067792215815971404\ \(0\)\
\-\ local\\:\\ 0\\.0067792215815971404\ \(0\)\
\-\ evaluated\\:\\ 0\\.006766284324724674\ \(0\)\
\-\ regions\\:\\ 0\\.006753443256525162\ \(0\)\
\-\ margins\\:\\ 0\\.006703012937540252\ \(0\)\
\-\ reaction\\:\\ 0\\.006703012937540252\ \(0\)\
\-\ 21\\:\\ 0\\.006678339436249274\ \(0\)\
\-\ removed\\:\\ 0\\.006654013460633145\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.006641977762332466\ \(0\)\
\-\ even\\:\\ 0\\.006571473454007327\ \(0\)\
\-\ worse\\:\\ 0\\.006537272025171092\ \(0\)\
\-\ necessary\\:\\ 0\\.006537272025171092\ \(0\)\
\-\ pathologic\\:\\ 0\\.006460007959814631\ \(0\)\
\-\ point\\:\\ 0\\.0064492470794162956\ \(0\)\
\-\ 60\\:\\ 0\\.006438552830283444\ \(0\)\
\-\ below\\:\\ 0\\.006406861744500721\ \(0\)\
\-\ not\\:\\ 0\\.006398024205916764\ \(0\)\
\-\ extends\\:\\ 0\\.006396425968238264\ \(0\)\
\-\ affected\\:\\ 0\\.006386052869688676\ \(0\)\
\-\ near\\:\\ 0\\.006386052869688676\ \(0\)\
\-\ lateral\\:\\ 0\\.006378818810447497\ \(0\)\
\-\ femur\\:\\ 0\\.006375741700454644\ \(0\)\
\-\ 2\\:\\ 0\\.006356146792782543\ \(0\)\
\-\ measures\\:\\ 0\\.006315134930486993\ \(0\)\
\-\ good\\:\\ 0\\.006315134930486993\ \(0\)\
\-\ rim\\:\\ 0\\.006247014495165237\ \(0\)\
\-\ ed\\:\\ 0\\.006237498682020211\ \(0\)\
\-\ general\\:\\ 0\\.006218622912534564\ \(0\)\
\-\ distress\\:\\ 0\\.006218622912534564\ \(0\)\
\-\ 40\\:\\ 0\\.006209261828822406\ \(0\)\
\-\ outside\\:\\ 0\\.0061906905131466515\ \(0\)\
\-\ a\\:\\ 0\\.006164763758838361\ \(0\)\
\-\ around\\:\\ 0\\.006145117533572913\ \(0\)\
\-\ specific\\:\\ 0\\.006100716226646822\ \(0\)\
\-\ line\\:\\ 0\\.006065999163916101\ \(0\)\
\-\ thin\\:\\ 0\\.006065999163916101\ \(0\)\
\-\ pathology\\:\\ 0\\.00604041179641154\ \(0\)\
\-\ upon\\:\\ 0\\.00603196622595525\ \(0\)\
\-\ fibrous\\:\\ 0\\.005965848459856775\ \(0\)\
\-\ 25\\:\\ 0\\.005965848459856775\ \(0\)\
\-\ additional\\:\\ 0\\.005917869938082897\ \(0\)\
\-\ routine\\:\\ 0\\.005917869938082897\ \(0\)\
\-\ extensive\\:\\ 0\\.005902168777977107\ \(0\)\
\-\ progressive\\:\\ 0\\.005833228177967708\ \(0\)\
\-\ seen\\:\\ 0\\.005832910587453161\ \(0\)\
\-\ is\\:\\ 0\\.005826847444401302\ \(0\)\
\-\ removal\\:\\ 0\\.00581827470172744\ \(0\)\
\-\ rate\\:\\ 0\\.005752541434327881\ \(0\)\
\-\ rare\\:\\ 0\\.005731174781819164\ \(0\)\
\-\ about\\:\\ 0\\.005689218490680918\ \(0\)\
\-\ 30\\:\\ 0\\.005675456539646071\ \(0\)\
\-\ 50\\:\\ 0\\.005614849769678419\ \(0\)\
\-\ lungs\\:\\ 0\\.005588581343661961\ \(0\)\
\-\ referred\\:\\ 0\\.005569138935156548\ \(0\)\
\-\ management\\:\\ 0\\.005569138935156548\ \(0\)\
\-\ occur\\:\\ 0\\.005537213521211638\ \(0\)\
\-\ throughout\\:\\ 0\\.0055246067811743115\ \(0\)\
\-\ metastasis\\:\\ 0\\.0055246067811743115\ \(0\)\
\-\ which\\:\\ 0\\.005509998574240237\ \(0\)\
\-\ laboratory\\:\\ 0\\.005438845830490615\ \(0\)\
\-\ ap\\:\\ 0\\.005397511173821136\ \(0\)\
\-\ very\\:\\ 0\\.005357142691635801\ \(0\)\
\-\ malignant\\:\\ 0\\.005334491669048879\ \(0\)\
\-\ intensity\\:\\ 0\\.005334491669048879\ \(0\)\
\-\ otherwise\\:\\ 0\\.005301062579320112\ \(0\)\
\-\ extension\\:\\ 0\\.0052682682576539784\ \(0\)\
\-\ the\\:\\ 0\\.005252995273712898\ \(0\)\
\-\ that\\:\\ 0\\.005098379027837041\ \(0\)\
\-\ long\\:\\ 0\\.005088465476395032\ \(0\)\
\-\ for\\:\\ 0\\.005037016570934128\ \(0\)\
\-\ does\\:\\ 0\\.005035614974756487\ \(0\)\
\-\ cause\\:\\ 0\\.004993545123578525\ \(0\)\
\-\ 10\\:\\ 0\\.004975171378837496\ \(0\)\
\-\ available\\:\\ 0\\.0049615182190670066\ \(0\)\
\-\ followed\\:\\ 0\\.0049479721440047865\ \(0\)\
\-\ palpation\\:\\ 0\\.004925628808891282\ \(0\)\
\-\ swelling\\:\\ 0\\.004916771785805065\ \(0\)\
\-\ white\\:\\ 0\\.004894825928690877\ \(0\)\
\-\ unremarkable\\:\\ 0\\.004886125075443973\ \(0\)\
\-\ past\\:\\ 0\\.004689463682118193\ \(0\)\
\-\ between\\:\\ 0\\.004677885209368297\ \(0\)\
\-\ right\\:\\ 0\\.00467166688658247\ \(0\)\
\-\ known\\:\\ 0\\.004670209126880517\ \(0\)\
\-\ area\\:\\ 0\\.004666383841337249\ \(0\)\
\-\ aspect\\:\\ 0\\.0046360827883995806\ \(0\)\
\-\ normal\\:\\ 0\\.0046273314493924045\ \(0\)\
\-\ show\\:\\ 0\\.004530493841954449\ \(0\)\
\-\ during\\:\\ 0\\.004516423574997941\ \(0\)\
\-\ as\\:\\ 0\\.004464861851102341\ \(0\)\
\-\ proximal\\:\\ 0\\.004430989951134741\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.0044110997230491465\ \(0\)\
\-\ 6\\:\\ 0\\.004407806841752805\ \(0\)\
\-\ in\\:\\ 0\\.004366810675028548\ \(0\)\
\-\ years\\:\\ 0\\.004333753259099279\ \(0\)\
\-\ lung\\:\\ 0\\.0042748862180289225\ \(0\)\
\-\ s\\:\\ 0\\.0042327593559837425\ \(0\)\
\-\ when\\:\\ 0\\.004226824244587229\ \(0\)\
\-\ appearance\\:\\ 0\\.004220909458954475\ \(0\)\
\-\ syndrome\\:\\ 0\\.004220909458954475\ \(0\)\
\-\ abnormal\\:\\ 0\\.004209140311424717\ \(0\)\
\-\ region\\:\\ 0\\.0041685686135394\ \(0\)\
\-\ 4\\:\\ 0\\.004112213998582116\ \(0\)\
\-\ mass\\:\\ 0\\.0041052193676945235\ \(0\)\
\-\ high\\:\\ 0\\.004038939656436641\ \(0\)\
\-\ months\\:\\ 0\\.004030986692038113\ \(0\)\
\-\ one\\:\\ 0\\.003999536067894031\ \(0\)\
\-\ at\\:\\ 0\\.00399918187506609\ \(0\)\
\-\ cyst\\:\\ 0\\.003966098680528675\ \(0\)\
\-\ fracture\\:\\ 0\\.003891320086826906\ \(0\)\
\-\ mild\\:\\ 0\\.0038864481069622397\ \(0\)\
\-\ than\\:\\ 0\\.0038670964679072086\ \(0\)\
\-\ over\\:\\ 0\\.0037575865114679837\ \(0\)\
\-\ on\\:\\ 0\\.003750730634017762\ \(0\)\
\-\ metastatic\\:\\ 0\\.00371521485944057\ \(0\)\
\-\ more\\:\\ 0\\.003691150793285261\ \(0\)\
\-\ to\\:\\ 0\\.0036879802110793285\ \(0\)\
\-\ acute\\:\\ 0\\.0036440057497521506\ \(0\)\
\-\ of\\:\\ 0\\.0036218798175540446\ \(0\)\
\-\ into\\:\\ 0\\.003511789927391549\ \(0\)\
\-\ \\;\\:\\ 0\\.00349813676762106\ \(0\)\
\-\ associated\\:\\ 0\\.0034826641829148563\ \(0\)\
\-\ imaging\\:\\ 0\\.003457813168317103\ \(0\)\
\-\ woman\\:\\ 0\\.003409158803953206\ \(0\)\
\-\ most\\:\\ 0\\.0034073145798412365\ \(0\)\
\-\ present\\:\\ 0\\.0033333484523863223\ \(0\)\
\-\ large\\:\\ 0\\.0032271890014353706\ \(0\)\
\-\ demonstrates\\:\\ 0\\.00322387081459963\ \(0\)\
\-\ have\\:\\ 0\\.0031959206880226108\ \(0\)\
\-\ and\\:\\ 0\\.003108963829571994\ \(0\)\
\-\ surgical\\:\\ 0\\.003102282850175222\ \(0\)\
\-\ after\\:\\ 0\\.0030535426642645984\ \(0\)\
\-\ treatment\\:\\ 0\\.0029872486348892693\ \(0\)\
\-\ has\\:\\ 0\\.002771502539713779\ \(0\)\
\-\ with\\:\\ 0\\.002627036768857628\ \(0\)\
\-\ \\(\\:\\ 0\\.0024952045811532314\ \(0\)\
\-\ \\)\\:\\ 0\\.0024647243250891368\ \(0\)\
\-\ by\\:\\ 0\\.002457462699904792\ \(0\)\
\-\ \\.\\:\\ 0\\.0024524722692467202\ \(0\)\
\-\ disease\\:\\ 0\\.002412327359612615\ \(0\)\
\-\ an\\:\\ 0\\.002040871959040984\ \(0\)\
\-\ was\\:\\ 0\\.0017068696411289927\ \(0\)\
\-\ this\\:\\ 0\\.0016599951870710414\ \(0\)\
\-\ left\\:\\ 0\\.0016513044374316316\ \(0\)\
\-\ year\\:\\ 0\\.0016513044374316316\ \(0\)\
\-\ old\\:\\ 0\\.0015111132933717695\ \(0\)\
\-\ patient\\:\\ 0\\.0014794333867295128\ \(0\)\
